Alpha Cognition Inc. announced that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer's Disease. The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of ALPHA-1062. The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of ALPHA-1062; If approved, the patent will provide protection for ALPHA-1062 into 2044, adding to other patent protection that currently protect ALPHA-1062 through 2042.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 CAD | 0.00% | +1.49% | +3.03% |
04-04 | Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period | MT |
04-04 | Alpha Cognition Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+3.03% | 74.55M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- ACOG Stock
- News Alpha Cognition Inc.
- Alpha Cognition Inc. Files Composition-Of-M Matter Patent